Sintilimab
- Generic Name
- Sintilimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2072873-06-2
- Unique Ingredient Identifier
- 8FU7FQ8UPK
- Associated Conditions
- -
- Associated Therapies
- -
Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-11-15
- Last Posted Date
- 2023-03-21
- Target Recruit Count
- 30
- Registration Number
- NCT05616390
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-11-15
- Last Posted Date
- 2022-11-15
- Lead Sponsor
- Wuhan Union Hospital, China
- Target Recruit Count
- 43
- Registration Number
- NCT05617430
- Locations
- 🇨🇳
Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China
A Biomarker Study for Predicting the Efficacy of Neoadjuvant Sintilimab Plus SOX for Gastric Adenocarcinoma.
- First Posted Date
- 2022-10-26
- Last Posted Date
- 2022-10-26
- Target Recruit Count
- 90
- Registration Number
- NCT05594381
Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-09-30
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT05562297
- Locations
- 🇨🇳
Zhongshan Hospital, Shanghai, Shanghai, China
Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-09-06
- Last Posted Date
- 2022-09-06
- Lead Sponsor
- Wuhan Union Hospital, China
- Target Recruit Count
- 36
- Registration Number
- NCT05527821
- Locations
- 🇨🇳
Union hospital, Wuhan, Hubei, China
Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis
- Conditions
- Interventions
- First Posted Date
- 2022-09-01
- Last Posted Date
- 2022-09-01
- Target Recruit Count
- 30
- Registration Number
- NCT05524155
Efficacy and Safety of IBI351 in Combination With Sintilimab ± Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation
- Conditions
- Interventions
- First Posted Date
- 2022-08-17
- Last Posted Date
- 2023-05-30
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 144
- Registration Number
- NCT05504278
- Locations
- 🇨🇳
Jilin Province Cancer Hospital, Jilin, Changchun, China
Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma
- First Posted Date
- 2022-08-10
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 219
- Registration Number
- NCT05495152
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-08-02
- Last Posted Date
- 2022-08-02
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 588
- Registration Number
- NCT05484024
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, Beijing, China
🇨🇳National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China
Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-08-01
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 32
- Registration Number
- NCT05481476
- Locations
- 🇨🇳
Cancer center of SunYat-sen University, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.